diabetes - Page 1 | CARLAT PUBLISHING

Clinical Update

Tapering Antipsychotics

November 1, 2023

Charmi Patel Rao, MD, DFAACAP. Director of Psychiatric Services, Positive Development; Health Sciences Assistant Clinical Professor, Department of Psychiatry, Child and Adolescent Psychiatry; UCSD, San Diego, CA.

Dr. Patel Rao has no financial relationships with companies related to this material.

Antipsychotics offer remarkable, even lifesaving treatment for children and adolescents, however, their side effects include metabolic and neurologic problems, including neurotoxicity. This clinical update guides you through a rational process for employing these powerful medications when necessary but also reducing and discontinuing them when possible.

Management of Psychogenic Polydipsia

July 11, 2022

Victoria Hendrick, MD and Zachary Davis

Psychogenic polydipsia (PP), also known as primary polydipsia and potomania, was first described in the 1930s. It is surprisingly common with a prevalence rate between 3 to 25% in institutionalized patients. In this podcast, we will discuss how to accurately diagnose and manage psychogenic polydipsia in patients.

RESEARCH UPDATE

Omega-3s and Metabolic Risks in Schizophrenia

September 28, 2021

Batya Swift Yasgur, MA, LSW, and Chris Aiken, MD.

Batya Swift Yasgur, MA, LSW, and Chris Aiken, MD. The authors have disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

Omega-3s are helpful for negative symptoms in schizophrenia, and this study suggests they may have metabolic benefits as well.

Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain

July 14, 2021

Farah Khorassani, PharmD. Clinical Assistant

Farah Khorassani, PharmD. Clinical Assistant Professor of Pharmacy Practice, St. John’s University, Queens, NY. Dr. Khorassani has disclosed no relevant financial or other interests in any commercial companies pertaining to this educational activity.

With so many weight loss medications on the market, it’s hard to know which to choose. Dr. Khorassani tells us everything we need to know to about selecting and prescribing these agents. Also, she gives us additional tips for managing antipsychotic-induced weight gain.

Weight Gain and Metabolic Side Effects

July 14, 2021

Stephen Marder, MD

Stephen Marder, MD

Daniel X. Freedman Professor of Psychiatry. Vice Chair for Education, Semel Institute for Neuroscience at UCLA. Director, VA VISN 22 Mental Illness Research, Education, and Clinical Center, San Diego, CA.

Dr. Marder has disclosed no relevant financial or other interests in any commercial companies pertaining to educational activity.

Dr. Steve Marder describes interventions to minimize patients’ antipsychotic-induced weight gain and insulin resistance.

Items Tagged with 'diabetes'

ARTICLES

Tapering Antipsychotics

Management of Psychogenic Polydipsia

Omega-3s and Metabolic Risks in Schizophrenia

Battle of the Bulge: Obesity and Antipsychotic-Induced Weight Gain

Weight Gain and Metabolic Side Effects

Hospital Psychiatry Fact Book, First Edition (2025) - Spiral Bound

KarXT (Cobenfy): The Breakthrough Antipsychotic That Could Change Everything

Psychopharm Secrets: Coming Off Meds

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

Join Our Writing Team

Insights About a Rare Transmissible Form of Alzheimer's Disease

How to Fulfill the DEA's One Time, 8-Hour Training Requirement for Registered Practitioners

About

Shop Online

Newsletters

Contact

Follow Us